ATE462414T1 - Irbesartan enthaltende feste zubereitung - Google Patents

Irbesartan enthaltende feste zubereitung

Info

Publication number
ATE462414T1
ATE462414T1 AT06000329T AT06000329T ATE462414T1 AT E462414 T1 ATE462414 T1 AT E462414T1 AT 06000329 T AT06000329 T AT 06000329T AT 06000329 T AT06000329 T AT 06000329T AT E462414 T1 ATE462414 T1 AT E462414T1
Authority
AT
Austria
Prior art keywords
preparation containing
solid preparation
irbesartan
containing irbesartan
active ingredient
Prior art date
Application number
AT06000329T
Other languages
English (en)
Inventor
Miha Vrbinc
Renata Jakse
Franci Bevec
Silvo Zupancic
Original Assignee
Krka D D Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka D D Novo Mesto filed Critical Krka D D Novo Mesto
Application granted granted Critical
Publication of ATE462414T1 publication Critical patent/ATE462414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06000329T 2006-01-09 2006-01-09 Irbesartan enthaltende feste zubereitung ATE462414T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06000329A EP1806130B1 (de) 2006-01-09 2006-01-09 Irbesartan enthaltende feste Zubereitung

Publications (1)

Publication Number Publication Date
ATE462414T1 true ATE462414T1 (de) 2010-04-15

Family

ID=35744710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06000329T ATE462414T1 (de) 2006-01-09 2006-01-09 Irbesartan enthaltende feste zubereitung

Country Status (15)

Country Link
US (1) US20110045097A1 (de)
EP (2) EP1806130B1 (de)
CN (1) CN101370484B (de)
AT (1) ATE462414T1 (de)
CA (1) CA2636663A1 (de)
DE (1) DE602006013261D1 (de)
EA (1) EA016579B1 (de)
ES (1) ES2340701T3 (de)
HR (1) HRP20100216T1 (de)
NO (1) NO20083183L (de)
PL (1) PL1806130T3 (de)
PT (1) PT1806130E (de)
SI (1) SI1806130T1 (de)
UA (1) UA95274C2 (de)
WO (1) WO2007080074A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006006588A1 (de) 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
UA96476C2 (ru) * 2007-04-17 2011-11-10 Ратиофарм Гмбх Фармацевтические композиции, которые содержат ирбесартан
EP2065035B1 (de) 2007-11-28 2010-07-21 Laboratorios Lesvi, S.L. Pharmazeutische Formulierungen mit Irbesartan
WO2011141783A2 (en) 2010-04-13 2011-11-17 Micro Labs Limited Pharmaceutical composition comprising irbesartan
CN101912390A (zh) * 2010-08-08 2010-12-15 浙江华海药业股份有限公司 含厄贝沙坦的药用组合物
CN103191076B (zh) * 2013-04-27 2016-08-17 吕丕平 一种厄贝沙坦片剂的制备方法
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (de) 1990-03-20 1993-03-11 Sanofi Co
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
CA2469656A1 (en) 2001-12-10 2003-06-19 Dr. Reddy's Laboratories Limited Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
ATE340793T1 (de) 2002-07-16 2006-10-15 Teva Pharma Neue synthese von irbesartan
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
EP1750862B1 (de) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation

Also Published As

Publication number Publication date
EP1981485B1 (de) 2014-10-08
DE602006013261D1 (de) 2010-05-12
CN101370484A (zh) 2009-02-18
EA016579B1 (ru) 2012-06-29
US20110045097A1 (en) 2011-02-24
PT1806130E (pt) 2010-05-11
PL1806130T3 (pl) 2010-08-31
CN101370484B (zh) 2011-06-01
SI1806130T1 (sl) 2010-06-30
EP1806130A1 (de) 2007-07-11
WO2007080074A1 (en) 2007-07-19
HRP20100216T1 (hr) 2010-05-31
EP1981485A1 (de) 2008-10-22
ES2340701T3 (es) 2010-06-08
CA2636663A1 (en) 2007-07-19
NO20083183L (no) 2008-09-26
EA200801634A1 (ru) 2008-10-30
EP1806130B1 (de) 2010-03-31
UA95274C2 (ru) 2011-07-25

Similar Documents

Publication Publication Date Title
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
NO20043367L (no) Oralt farmasoytisk preparat
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NO20081844L (no) Terapeutiske forbindelser
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
EP2246051A4 (de) Verfahren zur herstellung einer rasch im mund zerfallenden tablette mit imidafenacin als wirkstoff
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
ATE536172T1 (de) Ezetimibzusammensetzungen
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
PL2094308T3 (pl) Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
WO2007014124A3 (en) High drug load formulations and dosage forms
ATE537822T1 (de) Antidepressivum
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
TW200744583A (en) Statin stabilizing dosage formulations
CY1114306T1 (el) Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας
UA96575C2 (en) Process for the preparation of olmesartan medoxomil

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties